Drug Trial Radar · NCT03492125
A Study Of The Selective PKC-β Inhibitor MS- 553
Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
60
Actual
Start
May 25, 2018
Primary completion
Nov 28, 2023
Study completion Nov 28, 2023
Sponsor
- Lead sponsor
- MingSight Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Aggressive Lymphoma
Interventions
MS-553Drug
Oral, multiple dose levels
MS-553Drug
Oral recommended phase 2 dose of MS-553
acalabrutinibDrug
Oral
venetoclaxDrug
Oral
RituximabDrug
IV
obinutuzumabDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Incidence Rate of DLT and TEAE Requiring Study Drug DiscontinuationTime frame: Assessments for DLT and TEAE will occur during Cycle 1 (28 days) for A1 Cohort and B1 Cohort and Cycles 1-4 (up to 112 days) for C1 Cohort.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University Of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Columbia University, Herbert Irving Comprehensive Cancer Center
New York, New York
The Ohio State University, James Comprehensive Cancer Center
Columbus, Ohio
MD Anderson Cancer Center, Department of Leukemia
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.